Bridgeway Capital Management’s TScan Therapeutics TCRX Stock Holding History

Bridgeway Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$113K	Sell	111,900 -3,500	-3%	-$3.74K	﹤0.01%	1114
2025 Q4	$115K	Sell	115,400 -25,000	-18%	-$36.2K	﹤0.01%	1112
2025 Q3	$256K	Sell	140,400 -13,300	-9%	-$23.6K	0.01%	965
2025 Q2	$223K	Buy	153,700 +40,400	+36%	+$58.4K	0.01%	939
2025 Q1	$156K	Buy	113,300 +7,400	+7%	+$16K	﹤0.01%	969
2024 Q4	$322K	Buy	105,900 +67,600	+177%	+$306K	0.01%	907
2024 Q3	$191K	Hold	38,300	–	–	﹤0.01%	1078
2024 Q2	$224K	Sell	38,300 -25,000	-39%	-$197K	0.01%	1035
2024 Q1	$503K	Sell	63,300 -25,000	-28%	-$157K	0.01%	925
2023 Q4	$515K	Hold	88,300	–	–	0.01%	937
2023 Q3	$226K	Buy	88,300 +38,300	+77%	+$89.4K	0.01%	1075
2023 Q2	$125K	Sell	50,000 -65,000	-57%	-$174K	﹤0.01%	1222
2023 Q1	$242K	Hold	115,000	–	–	0.01%	1067
2022 Q4	$187K	Hold	115,000	–	–	﹤0.01%	1100
2022 Q3	$351K	Hold	115,000	–	–	0.01%	990
2022 Q2	$362K	Hold	115,000	–	–	0.01%	952
2022 Q1	$322K	Buy	115,000 +75,000	+188%	+$324K	0.01%	1052
2021 Q4	$180K	Buy	+40,000	New	+$289K	﹤0.01%	1173

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Bridgeway Capital Management's TCRX Position: Q1 2026 in Review

Bridgeway Capital Management reduced its TScan Therapeutics (TCRX) stake by 3% in Q1 2026, selling an estimated $3.74K and leaving 111,900 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #1114.

Bridgeway Capital Management first reported a position in TCRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $515K in Q4 2023. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Bridgeway Capital Management held 111,900 shares of TScan Therapeutics worth $113K as of Q1 2026.
Bridgeway Capital Management sold 3,500 TScan Therapeutics shares in Q1 2026, an estimated $3.74K.
TScan Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1114 holding.
Bridgeway Capital Management first reported a position in TScan Therapeutics in Q4 2021 and has held it in 18 quarters since.
Bridgeway Capital Management's TScan Therapeutics position peaked at $515K in Q4 2023.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.